Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Dechra Pharmaceuticals Company

DPH.L
GB0009633180
578968

Price

38.66
Today +/-
+0
Today %
+0 %
P

Dechra Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Dechra Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Dechra Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Dechra Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Dechra Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Dechra Pharmaceuticals Stock Price History

DateDechra Pharmaceuticals Price
1/16/202438.66 undefined
1/15/202438.66 undefined

Dechra Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dechra Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dechra Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dechra Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dechra Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dechra Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dechra Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dechra Pharmaceuticals’s growth potential.

Dechra Pharmaceuticals Revenue, EBIT and net profit per share

DateDechra Pharmaceuticals RevenueDechra Pharmaceuticals EBITDechra Pharmaceuticals Net Income
2028e1.07 B undefined0 undefined230.69 M undefined
2027e1 B undefined256.68 M undefined179.94 M undefined
2026e982.83 M undefined192.99 M undefined203.81 M undefined
2025e926.35 M undefined184.46 M undefined166.98 M undefined
2024e851.26 M undefined157.7 M undefined147.77 M undefined
2023761.5 M undefined24.9 M undefined-27.9 M undefined
2022681.8 M undefined101.5 M undefined58.2 M undefined
2021608 M undefined87 M undefined55.5 M undefined
2020515.1 M undefined58.7 M undefined33.9 M undefined
2019481.8 M undefined50.6 M undefined30.9 M undefined
2018407.1 M undefined45.1 M undefined36.1 M undefined
2017359.28 M undefined40.91 M undefined26.11 M undefined
2016247.56 M undefined32.71 M undefined12.67 M undefined
2015203.48 M undefined26.48 M undefined19.46 M undefined
2014193.6 M undefined25.6 M undefined59 M undefined
2013189.2 M undefined20.9 M undefined17.9 M undefined
2012426 M undefined25.7 M undefined11.7 M undefined
2011389.2 M undefined22.9 M undefined14.1 M undefined
2010369.4 M undefined21.2 M undefined13.2 M undefined
2009350 M undefined17.7 M undefined11.3 M undefined
2008304.4 M undefined14.1 M undefined8.3 M undefined
2007253.8 M undefined13.8 M undefined8.8 M undefined
2006232.5 M undefined12.3 M undefined7.6 M undefined
2005208.2 M undefined10.4 M undefined6.3 M undefined
2004186.8 M undefined8.6 M undefined5.1 M undefined

Dechra Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
0.150.160.170.180.190.210.230.250.30.350.370.390.430.190.190.20.250.360.410.480.520.610.680.760.850.930.9811.07
-7.598.975.293.9111.8311.549.0520.1615.135.435.429.51-55.632.125.1821.6745.3413.3718.187.0718.0612.0111.7511.838.816.052.147.08
11.0312.1811.7612.8513.4413.9414.2214.2317.4320.8621.6822.6223.2452.9155.4457.1455.8754.3255.7757.8056.5056.7456.5356.37-----
1619202325293336537380889910010711613819522727829134538542900000
788781012131417212225202526324045505887101241571841922560
4.835.134.713.914.304.815.175.144.614.865.695.665.8710.5812.9512.8112.9611.1411.0610.4011.2614.3114.833.1518.4519.8719.5525.52-
1353567881113141117591912263630335558-27147166203179230
-200.0066.67-40.0066.6720.0016.6714.29-37.5018.187.69-21.4354.55247.06-67.80-36.84116.6738.46-16.6710.0066.675.45-146.55-644.4412.9322.29-11.8228.49
-----------------------------
-----------------------------
29.749.956.357.458.158.359.159.865.172.87372.475.387.687.788.590.0193.4897.45102.76103.48108.75108.99113.4800000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Dechra Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Dechra Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
9.2400013.919.717.222.226.831.530.532.432.826.846.5339.2761.279.780.3227.4118.4120.974.4
20.723.224.626.831.331.833.53443.74548.362.269.625.328.327.7159.2359.687691.179.488.2122.1144.2
1.50.70.80.80.91.111.41.211.52.510.90.91.278.085.5312.717.9312025.4
16.216.519.317.31720.42225.732.431.534.840.857.329.229.731.7454.3856.5186.6103.5120.8149.5175.7217.3
0.20.20.40.40.70.80.80.82.51.71.31.61.691.30.71.381.422.092.63.93.45.15.76.6
47.844.645.145.349.9687779.1102106117.4137.6161.9179.586.4108.62162.39184.98247.9291.5448.9392.2444.4467.9
2.64.36.35.65.25.25.65.78.287.77.716.716.118.316.8237.7245.245.358.476.487100.3159.3
0000000000000000010.8510.510.117.417.115.814.9
00000000000000000000002025.4
0000.80.81.93.18.270.568.559.9100.8168161.2141.2117.36242.08268.13480.5434.9438.4479.7485.1587.9
005.34.94.43.84.44.919.821.120.524.257.958.45549.33113.18128.13229.3245.7253.8236.1245.4334.5
0000000.401.100000000.470.783.80.92.722.34.9
000.010.010.010.010.010.020.10.10.090.130.240.240.210.180.390.450.770.750.790.820.871.13
0.050.050.060.060.060.080.090.10.20.20.210.270.40.420.30.290.560.641.021.041.241.211.311.59
                                               
00.51.30.50.50.50.50.50.70.70.70.70.90.90.90.880.930.93111.11.11.11.1
0.626.826.826.826.82727.72862.262.46363.6122.6123.5124.4124.8172.45173.38359.3277.9409.3411.6413.9596
-28.6-26.4-22.3-19.8-17.1-13-4.227.113.621.529.734.141.289.396.7595.77109.19127.3208.6210.8232.1248.4171
000000-0.1-0.11.941.14.5-49.1-9.2-27.645.5118.2417.821.616.3-11.93.4-12.7
000000000000000000000000
-280.95.87.510.214.523.930.471.980.786.398.5153.6174.7205.4194.79274.65301.74505.4509.1637.5632.9666.8755.4
34.531.131.729.233.238.2424450.249.256.563.263.611.912.910.3724.3321.433331.934.635.24643.4
1.51.71.42.33.53.33.1476.94.56.29.29.65.712.718.3621.1630.461.760.574.487.798.8
1.22.832.73.14.233.18.210.47.711.12571.717.121.0321.6222.842723.337.643.121.717.9
000000000000000000000000
3.33.46.38.35.31.53.44.521.219.320.48.55.710.30.10.011.670.971.21.24.63.13.33.9
40.53942.442.545.147.251.555.686.685.889.189103.5103.535.844.1165.9866.4191.6118.1137.3155.8158.7164
33.598.56.74.817.315.211.72823.117.856.1114105.23232.52154.44180.54293.3309.6353.1317.6325.8500.6
00000.2000.115.314.212.513.429.327.221.516.2948.9249.2796.874.562.648.835.876.3
4.500.10000000013.63.94.66.74.729.8839.2130.630.247.159106.273.3
3898.66.7517.315.211.843.337.330.383.1147.213760.253.53213.23269.02420.7414.3462.8425.4467.8650.2
78.5485149.250.164.566.767.4129.9123.1119.4172.1250.7240.59697.64279.22335.43512.3532.4600.1581.2626.5814.2
0.050.050.060.060.060.080.090.10.20.20.210.270.40.420.30.290.550.641.021.041.241.211.291.57
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Dechra Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Dechra Pharmaceuticals's financial health and stability.

Assets

Dechra Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Dechra Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Dechra Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Dechra Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
778781078811131411175919193334395284956
011111114891114222021767914158989
000000000000000000000000
0-13-6-5-2-2-4-6-10-6-12-17-17-16-36-8-14-9-40-46-29-88-68-105
0000005566781012-318314763796977673
3711121244332421145988718
01221222336577941112111712433227
8-5337999820171619361140437764811068912263
0-1-2-20-1-1-5-2-3-2-4-8-9-7-3-7-10-12-22-49-134-77-30
-1-1-6-10-10-4-65-1-1-36-120-1976-4-174-57-241-61-81-136-78-426
00-310000-6321-32-111-10830-166-46-229-39-32-10-395
000000000000000000000000
-2-240-3-2110-333-9-52655-7-7909319116722-19-3186
0270000003500060000470103113122181
-22-2-5-49-2-662-14-1018103-18-92-141251193-20118-55-46316
---------2.00----3.00---1.00---3.00--1.00---
00-1-2-2-2-2-3-4-5-6-7-8-11-12-13-15-17-21-28-33-37-44-51
4-5-6-32175-2444-110-619-622180147-1092-46
7.22-7.330.270.757.137.837.973.866.4416.6514.612.6610.8527.754.137.2236.0766.6851.459.357.2-45.745.333.3
000000000000000000000000

Dechra Pharmaceuticals stock margins

The Dechra Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dechra Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dechra Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dechra Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Dechra Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dechra Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dechra Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dechra Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dechra Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dechra Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dechra Pharmaceuticals Margin History

Dechra Pharmaceuticals Gross marginDechra Pharmaceuticals Profit marginDechra Pharmaceuticals EBIT marginDechra Pharmaceuticals Profit margin
2028e56.41 %0 %21.48 %
2027e56.41 %25.59 %17.94 %
2026e56.41 %19.64 %20.74 %
2025e56.41 %19.91 %18.03 %
2024e56.41 %18.53 %17.36 %
202356.41 %3.27 %-3.66 %
202256.51 %14.89 %8.54 %
202156.89 %14.31 %9.13 %
202056.61 %11.4 %6.58 %
201957.74 %10.5 %6.41 %
201855.88 %11.08 %8.87 %
201754.54 %11.39 %7.27 %
201655.95 %13.21 %5.12 %
201557.08 %13.01 %9.56 %
201455.63 %13.22 %30.48 %
201353.22 %11.05 %9.46 %
201223.31 %6.03 %2.75 %
201122.71 %5.88 %3.62 %
201021.82 %5.74 %3.57 %
200921.06 %5.06 %3.23 %
200817.61 %4.63 %2.73 %
200714.54 %5.44 %3.47 %
200614.32 %5.29 %3.27 %
200514.27 %5 %3.03 %
200413.6 %4.6 %2.73 %

Dechra Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Dechra Pharmaceuticals earnings per share therefore indicates how much revenue Dechra Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dechra Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dechra Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dechra Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dechra Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dechra Pharmaceuticals Revenue, EBIT and net profit per share

DateDechra Pharmaceuticals Sales per ShareDechra Pharmaceuticals EBIT per shareDechra Pharmaceuticals Earnings per Share
2028e9.43 undefined0 undefined2.03 undefined
2027e8.81 undefined0 undefined1.58 undefined
2026e8.63 undefined0 undefined1.79 undefined
2025e8.13 undefined0 undefined1.47 undefined
2024e7.47 undefined0 undefined1.3 undefined
20236.71 undefined0.22 undefined-0.25 undefined
20226.26 undefined0.93 undefined0.53 undefined
20215.59 undefined0.8 undefined0.51 undefined
20204.98 undefined0.57 undefined0.33 undefined
20194.69 undefined0.49 undefined0.3 undefined
20184.18 undefined0.46 undefined0.37 undefined
20173.84 undefined0.44 undefined0.28 undefined
20162.75 undefined0.36 undefined0.14 undefined
20152.3 undefined0.3 undefined0.22 undefined
20142.21 undefined0.29 undefined0.67 undefined
20132.16 undefined0.24 undefined0.2 undefined
20125.66 undefined0.34 undefined0.16 undefined
20115.38 undefined0.32 undefined0.19 undefined
20105.06 undefined0.29 undefined0.18 undefined
20094.81 undefined0.24 undefined0.16 undefined
20084.68 undefined0.22 undefined0.13 undefined
20074.24 undefined0.23 undefined0.15 undefined
20063.93 undefined0.21 undefined0.13 undefined
20053.57 undefined0.18 undefined0.11 undefined
20043.22 undefined0.15 undefined0.09 undefined

Dechra Pharmaceuticals business model

Dechra Pharmaceuticals PLC is a British company specializing in animal medicine. It was founded in 1997 and has experienced remarkable growth since then. Dechra is listed on the London Stock Exchange and has its headquarters in Northwich, Cheshire, UK. Dechra builds its business models on a broad portfolio of products and services. The company is primarily focused on the development and sale of pharmaceuticals and diagnostics tailored to the needs of veterinarians and pet owners. The company has an extensive range of animal medicines, divided into categories such as antibiotics, painkillers, and anti-inflammatory drugs. Dechra operates three major business segments that drive its growth: the veterinary medicines business, the diagnostics business, and the specialty pharma business. The veterinary medicines business is the core of Dechra's operations. Here, the company produces products that can be used on livestock and companion animals. Dechra dominates the animal medicine market in Europe and has also established itself in the field of animal health in the US. The diagnostics business is another important segment that focuses on diagnostics and tests to quickly and effectively diagnose animal diseases. These products are primarily sold to veterinarians and veterinary laboratories. Dechra's specialty pharma business focuses on the production of specialty drugs tailored to a specific animal species or a specific disease that affects rarer species. Producing such medications generally requires higher expertise and also results in higher profitability due to typically lower competition. In recent years, Dechra has accelerated its presence and growth through targeted acquisitions. These acquisitions have expanded both Dechra's portfolio and geographic reach. In 2014, Dechra acquired US-based Genera N.A., a specialized pharmaceutical company producing animal medicines. With the acquisition of Genera, Dechra was able to strengthen its presence in the US animal medicine market. The company has also made acquisitions in Europe, such as the acquisition of Eurovet Animal Health in 2020. Eurovet is a Netherlands-based company specializing in animal health products and covers important market regions in Europe. The acquisition of Eurovet has allowed Dechra to strengthen its presence in Germany and Scandinavia. In summary, Dechra Pharmaceuticals PLC is one of the leading companies in the animal medicine industry. The company has maintained its reputation by creating innovative products and services based on the highest manufacturing and operational standards. The company is committed to continuing to provide value to veterinarians and pet owners while improving the health and well-being of animals. Dechra Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Dechra Pharmaceuticals SWOT Analysis

Strengths

Weaknesses: Limited therapeutic areas: Dechra Pharmaceuticals primarily focuses on certain therapeutic areas within the veterinary pharmaceutical market. This limited scope may restrict the company's potential for growth in other segments. Dependency on key markets: The company's revenue is heavily reliant on a few key markets, making it vulnerable to changes in regulations, market conditions, or economic challenges in those regions. Intense competition: Dechra Pharmaceuticals operates in a highly competitive industry, facing competition from both global pharmaceutical companies and local players. This intense competition may impact market share and pricing power.

Opportunities: Emerging markets: The company can expand its presence in emerging markets where the demand for veterinary pharmaceuticals is growing due to increasing pet ownership and the overall rise in animal healthcare expenditure. Acquisitions and partnerships: Dechra Pharmaceuticals can consider strategic acquisitions or partnerships to access new technologies, expand its product portfolio, and strengthen market position in specific regions or therapeutic areas. E-commerce and online channels: Increasing digitalization and the rise of e-commerce present opportunities for Dechra Pharmaceuticals to enhance distribution channels and reach a broader customer base through online platforms.

Threats: Regulatory challenges: Stringent regulations and compliance requirements in the veterinary pharmaceutical industry may pose challenges for Dechra Pharmaceuticals, leading to delays in product approvals or increased regulatory costs. Market uncertainty: Factors such as economic instability, political uncertainties, or unexpected events (such as pandemics) can impact the demand for veterinary pharmaceuticals and disrupt supply chains, affecting Dechra Pharmaceuticals' operations. Product counterfeit and piracy: The company may face the risk of product counterfeiting or piracy, which can negatively impact brand reputation, sales revenue, and customer trust.

Weaknesses

Opportunities: Emerging markets: The company can expand its presence in emerging markets where the demand for veterinary pharmaceuticals is growing due to increasing pet ownership and the overall rise in animal healthcare expenditure. Acquisitions and partnerships: Dechra Pharmaceuticals can consider strategic acquisitions or partnerships to access new technologies, expand its product portfolio, and strengthen market position in specific regions or therapeutic areas. E-commerce and online channels: Increasing digitalization and the rise of e-commerce present opportunities for Dechra Pharmaceuticals to enhance distribution channels and reach a broader customer base through online platforms.

Threats: Regulatory challenges: Stringent regulations and compliance requirements in the veterinary pharmaceutical industry may pose challenges for Dechra Pharmaceuticals, leading to delays in product approvals or increased regulatory costs. Market uncertainty: Factors such as economic instability, political uncertainties, or unexpected events (such as pandemics) can impact the demand for veterinary pharmaceuticals and disrupt supply chains, affecting Dechra Pharmaceuticals' operations. Product counterfeit and piracy: The company may face the risk of product counterfeiting or piracy, which can negatively impact brand reputation, sales revenue, and customer trust.

Opportunities

Threats: Regulatory challenges: Stringent regulations and compliance requirements in the veterinary pharmaceutical industry may pose challenges for Dechra Pharmaceuticals, leading to delays in product approvals or increased regulatory costs. Market uncertainty: Factors such as economic instability, political uncertainties, or unexpected events (such as pandemics) can impact the demand for veterinary pharmaceuticals and disrupt supply chains, affecting Dechra Pharmaceuticals' operations. Product counterfeit and piracy: The company may face the risk of product counterfeiting or piracy, which can negatively impact brand reputation, sales revenue, and customer trust.

Threats

Dechra Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Dechra Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Dechra Pharmaceuticals shares outstanding

The number of shares was Dechra Pharmaceuticals in 2023 — This indicates how many shares 113.477 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dechra Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dechra Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dechra Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dechra Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dechra Pharmaceuticals dividend history and estimates

In 2023, Dechra Pharmaceuticals paid a dividend amounting to 0.25 GBP. Dividend means that Dechra Pharmaceuticals distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Dechra Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Dechra Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Dechra Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Dechra Pharmaceuticals Dividend History

DateDechra Pharmaceuticals Dividend
2028e0.25 undefined
2027e0.25 undefined
2026e0.25 undefined
2025e0.25 undefined
2024e0.25 undefined
20230.25 undefined
20220.45 undefined
20210.41 undefined
20200.34 undefined
20190.32 undefined
20180.26 undefined
20170.21 undefined
20160.18 undefined
20150.19 undefined
20140.17 undefined
20130.16 undefined
20120.14 undefined
20110.12 undefined
20100.11 undefined
20090.09 undefined
20080.08 undefined
20070.07 undefined
20060.06 undefined
20050.05 undefined
20040.05 undefined

Dechra Pharmaceuticals dividend payout ratio

In 2023, Dechra Pharmaceuticals had a payout ratio of 89.11%. The payout ratio indicates the percentage of the company's profits that Dechra Pharmaceuticals distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Dechra Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Dechra Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Dechra Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Dechra Pharmaceuticals Payout Ratio History

DateDechra Pharmaceuticals Payout ratio
2028e85.86 %
2027e85.44 %
2026e86.36 %
2025e85.78 %
2024e84.18 %
202389.11 %
202284.06 %
202179.36 %
2020103.91 %
2019105.33 %
201868.92 %
201776.77 %
2016131.16 %
201585.6 %
201425.54 %
201377.78 %
201284.84 %
201160.93 %
201058.75 %
200957.28 %
200863.92 %
200749.46 %
200647.48 %
200546.76 %
200451.66 %
Unfortunately, there are currently no price targets and forecasts available for Dechra Pharmaceuticals.

Dechra Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20210.49 0.54  (9.16 %)2021 Q4
12/31/20190.34 0.43  (29.58 %)2020 Q2
6/30/20190.45 0.48  (8.43 %)2019 Q4
12/31/20180.42 0.42  (-0.38 %)2019 Q2
12/31/20170.34 0.38  (10.82 %)2018 Q2
12/31/20090.12 0.14  (18.47 %)2010 Q2
1

Eulerpool ESG Scorecard© for the Dechra Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

79/ 100

🌱 Environment

88

👫 Social

92

🏛️ Governance

56

Environment

Scope 1 - Direct Emissions
6,709
Scope 2 - Indirect emissions from purchased energy
4,896
Scope 3 - Indirect emissions within the value chain
2,770
Total CO₂ emissions
11,605
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees53
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees87
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Dechra Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
6.67968 % Barclays Wealth7,608,559587,03910/20/2023
6.60013 % BNP Paribas Asset Management France SAS7,517,942-62,69710/20/2023
5.78774 % BlackRock Investment Management (UK) Ltd.6,592,587-282,91110/20/2023
4.79820 % Ostrum Asset Management5,465,4411,09510/20/2023
4.44057 % Société Générale Securities Services S.A.5,058,078-956,94310/20/2023
4.41911 % The Vanguard Group, Inc.5,033,62714,72110/19/2023
3.43139 % Norges Bank Investment Management (NBIM)3,908,560-20,9999/14/2023
3.05400 % Bank of Nova Scotia3,478,6911,155,81010/13/2023
2.97681 % NBC Global Finance, Ltd.3,390,768-1,214,81410/17/2023
2.94226 % Brown Capital Management, LLC3,351,410-134,11610/16/2023
1
2
3
4
5
...
10

Dechra Pharmaceuticals Executives and Management Board

Mr. Ian Page
Dechra Pharmaceuticals Chief Executive Officer, Executive Director (since 1997)
Compensation 2.07 M
Mr. Paul Sandland
Dechra Pharmaceuticals Chief Financial Officer, Executive Director (since 2010)
Compensation 932,000
Mr. Anthony Griffin
Dechra Pharmaceuticals Managing Director - Dechra Veterinary Products EU, Executive Director (since 2012)
Compensation 856,000
Ms. Alison Platt
Dechra Pharmaceuticals Non-Executive Independent Chairman of the Board
Compensation 132,000
Ms. Ishbel Macpherson61
Dechra Pharmaceuticals Non-Executive Independent Director
Compensation 83,000
1
2
3

Most common questions regarding Dechra Pharmaceuticals

What values and corporate philosophy does Dechra Pharmaceuticals represent?

Dechra Pharmaceuticals PLC represents a set of core values and a corporate philosophy that sets them apart in the pharmaceutical industry. With a strong focus on innovation, Dechra strives to improve animal health worldwide. Their commitment to research and development enables them to provide effective and safe veterinary products. Dechra emphasizes ethical behavior, transparency, and accountability in all their operations. They prioritize collaboration, both internally and externally, to foster strong partnerships and drive mutual success. By putting animals' well-being at the forefront, Dechra Pharmaceuticals PLC aims to make a positive impact on the lives of pets and livestock.

In which countries and regions is Dechra Pharmaceuticals primarily present?

Dechra Pharmaceuticals PLC is primarily present in multiple countries and regions. Some key regions where the company operates include North America, Europe, and Australia. In North America, Dechra Pharmaceuticals has a strong presence in the United States and Canada. In Europe, the company operates in countries such as the United Kingdom, Germany, France, Spain, Italy, and others. Additionally, Dechra Pharmaceuticals has a significant presence in Australia. Through its global presence, Dechra Pharmaceuticals PLC continues to expand its reach and provide veterinary pharmaceutical products and services to various markets worldwide.

What significant milestones has the company Dechra Pharmaceuticals achieved?

Dechra Pharmaceuticals PLC has achieved several significant milestones over the years. Firstly, in 2007, the company successfully acquired VetXX, expanding its product portfolio and strengthening its presence in the companion animal veterinary market. Additionally, in 2010, Dechra Pharmaceuticals acquired Eurovet Animal Health BV, further enhancing its product range and market reach. The company also achieved a major milestone in 2017 by receiving FDA approval for Zycortal, a treatment for canine Addison's disease. Furthermore, in 2019, Dechra Pharmaceuticals launched Osphos, a unique and innovative treatment for navicular syndrome in horses. These milestones highlight Dechra Pharmaceuticals PLC's commitment to continuous growth, product innovation, and expansion within the animal healthcare industry.

What is the history and background of the company Dechra Pharmaceuticals?

Dechra Pharmaceuticals PLC is a leading veterinary pharmaceutical company headquartered in the United Kingdom. Established in 1997, Dechra has built a strong reputation in developing, manufacturing, and marketing a wide range of specialized veterinary medicines and related products. With a focus on enhancing the well-being of animals and improving their quality of life, Dechra is dedicated to providing innovative solutions to veterinarians and pet owners worldwide. Over the years, it has expanded its presence globally and now operates in various countries. Dechra Pharmaceuticals PLC continues to strive for excellence in the field of veterinary healthcare, delivering high-quality products and driving advancements in animal medicine.

Who are the main competitors of Dechra Pharmaceuticals in the market?

The main competitors of Dechra Pharmaceuticals PLC in the market include companies such as Zoetis Inc., IDEXX Laboratories, Inc., Covetrus, Inc., and Virbac SA. These companies also operate in the animal healthcare industry and provide similar products and services. However, Dechra Pharmaceuticals PLC distinguishes itself through its unique product portfolio, strong distribution network, and focus on specialized veterinary medicine. With its commitment to innovation and customer-centric approach, Dechra Pharmaceuticals PLC successfully competes against these industry players to maintain its market position.

In which industries is Dechra Pharmaceuticals primarily active?

Dechra Pharmaceuticals PLC is primarily active in the veterinary healthcare industry.

What is the business model of Dechra Pharmaceuticals?

Dechra Pharmaceuticals PLC operates under a business model focused on the research, development, production, and marketing of veterinary pharmaceutical products. The company specializes in providing innovative solutions for veterinarians and pet owners, offering a wide range of prescription medications and other healthcare products for companion animals and livestock. Dechra Pharmaceuticals PLC strives to enhance animal health and welfare by delivering high-quality pharmaceuticals and supporting solutions. With its strong commitment to the veterinary industry, Dechra Pharmaceuticals PLC continues to contribute to the well-being of animals worldwide.

What is the P/E ratio of Dechra Pharmaceuticals 2024?

The Dechra Pharmaceuticals P/E ratio is 29.69.

What is the P/S ratio of Dechra Pharmaceuticals 2024?

The Dechra Pharmaceuticals P/S ratio is 5.15.

What is the Quality Investing of Dechra Pharmaceuticals?

The Quality Investing for Dechra Pharmaceuticals is 4/10.

What is the revenue of Dechra Pharmaceuticals 2024?

The expected Dechra Pharmaceuticals revenue is 851.26 M GBP.

How high is the profit of Dechra Pharmaceuticals 2024?

The expected Dechra Pharmaceuticals profit is 147.77 M GBP.

What is the business model of Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC is a globally operating animal pharmaceutical company based in the United Kingdom. Its core business consists of the development, manufacturing, and marketing of animal medications and equipment. The company operates in Europe, North America, and Australasia, employing over 2,200 people worldwide. The company is divided into several business divisions: Pharmaceuticals: In this area, Dechra offers a wide range of animal medicines, including veterinary medicines for pets such as dogs and cats, as well as for livestock such as pigs, cattle, and sheep. The range includes medications for infectious diseases, as well as inflammatory diseases, metabolic disorders, and cancer. Medical devices: The Medical Devices division is involved in the development, production, and marketing of medical devices and consumables for veterinary practices and clinics. This includes surgical instruments, catheters, syringes, and needles, for example. Services: Dechra offers services related to animal medicine, including continuing education for veterinarians, consulting for veterinary practices in setting up laboratories, and support for veterinary practices in the management of medications and instruments. Dechra's core business is the sale of animal medications. The company is committed to expanding its position as a leading provider of animal medications. To this end, Dechra invests heavily in research and development to develop new medications and improve existing ones. In addition, the company has made several acquisitions in recent years to expand its product portfolio and increase its global presence. An example of an acquisition is the purchase of Putney Inc. in 2016. Putney is a leading provider of animal medications for pets in the United States. With this acquisition, Dechra was able to strengthen its presence in the North American market and expand its portfolio of animal medications for dogs and cats. Another important factor for Dechra's success is its close collaboration with veterinarians. The company works closely with veterinarians to develop new medications and improve existing ones. Dechra also offers veterinarians continuing education to ensure they are always up to date with veterinary medicine. Overall, Dechra's business model is focused on supporting veterinarians in the treatment of animals. The company offers a broad portfolio of animal medications, medical devices, and services, and continually invests in research and development to ensure it provides the veterinary profession with the right solutions. With its global presence and close collaboration with veterinarians, Dechra is well positioned to continue to be successful in the future.

What is the Dechra Pharmaceuticals dividend?

Dechra Pharmaceuticals pays a dividend of 0.45 GBP distributed over payouts per year.

How often does Dechra Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Dechra Pharmaceuticals or the company does not pay out a dividend.

What is the Dechra Pharmaceuticals ISIN?

The ISIN of Dechra Pharmaceuticals is GB0009633180.

What is the Dechra Pharmaceuticals WKN?

The WKN of Dechra Pharmaceuticals is 578968.

What is the Dechra Pharmaceuticals ticker?

The ticker of Dechra Pharmaceuticals is DPH.L.

How much dividend does Dechra Pharmaceuticals pay?

Over the past 12 months, Dechra Pharmaceuticals paid a dividend of 0.25 GBP . This corresponds to a dividend yield of about 0.65 %. For the coming 12 months, Dechra Pharmaceuticals is expected to pay a dividend of 0.25 GBP.

What is the dividend yield of Dechra Pharmaceuticals?

The current dividend yield of Dechra Pharmaceuticals is 0.65 %.

When does Dechra Pharmaceuticals pay dividends?

Dechra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of November, April, November, April.

How secure is the dividend of Dechra Pharmaceuticals?

Dechra Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Dechra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.25 GBP are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dechra Pharmaceuticals located?

Dechra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dechra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dechra Pharmaceuticals from 4/13/2023 amounting to 0.125 GBP, you needed to have the stock in your portfolio before the ex-date on 3/9/2023.

When did Dechra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/13/2023.

What was the dividend of Dechra Pharmaceuticals in the year 2023?

In the year 2023, Dechra Pharmaceuticals distributed 0.449 GBP as dividends.

In which currency does Dechra Pharmaceuticals pay out the dividend?

The dividends of Dechra Pharmaceuticals are distributed in GBP.

All fundamentals about Dechra Pharmaceuticals

Our stock analysis for Dechra Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dechra Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.